Related Posts

• 
  The Role of Patient-reported Outcomes and Medication Adherence Assessment in Patient-focused Drug Development for Solid Organ Transplantation
• 
  Use of Biomarkers to Improve Immunosuppressive Drug Development and Outcomes in Renal Organ Transplantation: A Meeting Report
• 
  On September 25th, the FDA published a Personal Viewpoint in the American Journal of Transplantation
• 
  The Importance of Drug Safety and Tolerability in the Development of New Immunosuppressive Therapy for Transplant Recipients